ONO PHARMACEUTICAL CO., LTD.

May 10, 2018

Ono Pharmaceutical Co., Ltd. ("The Company") has announced its consolidated financial results ended March 31, 2018.

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRSs").

This Annual Flash Report for the year ended March 31, 2018 (unaudited) is summary information extracted from the financial statements announced, and the financial statements and the figures contained herein are prepared for reference only for the convenience of readers outside Japan with certain modifications and reclassifications made from the original financial statements presented in Japanese language.

The translations of Japanese yen amounts into U.S. dollar amounts are included solely for the convenience of readers outside Japan using the rate of \(\frac{\pma}{106}\) to \(\frac{\pma}{1}\), the approximate rate of exchange at March 30, 2018.

Amounts of less than one million yen and one thousand U.S. dollars have been rounded to the nearest million yen and one thousand U.S. dollars in the presentation of the accompanying consolidated financial statements.

Financial Highlights

Ono Pharmaceutical Co., Ltd. and Consolidated Subsidiaries

	Millions of yen				Thousands of US\$	
	Year ended March 31, 2017		Year ended March 31, 2018		Year ended March 31, 2018	
Revenue	¥	244,797	¥	261,836	\$	2,470,150
Profit (Owners of the parent compar	ny)	55,793		50,284		474,375
Total equity		524,211		529,619		4,996,403
Total assets		617,461		609,226		5,747,411 US\$
Basic earnings per share	¥	105.27	¥	97.00	\$	0.92
Diluted earnings per share	¥	105.26	¥	96.99	\$	0.92